Media

DES MOINES, IA–(Marketwired – Dec 3, 2013) – The SpendSmart Payments Company (OTCQB: SSPC), a provider of prepaid payment programs and a program manager platform, announced today that Joe Proto, who has served on the Company’s board since January of 2012, has been elected by the Board of Directors to become Chairman of the Board.

In conjunction with this change, Mike McCoy, the Company’s CEO, maintains his position on the Board as a Director. Jesse Itzler has resigned from his post as Director in order to devote more time to his family. The Board of Directors thanks Mr. Itzler for his valuable service and looks forward to a continued working relationship with him.

Joe Proto is a seasoned and successful senior executive and entrepreneur with three decades in the billing and payments industry. Mr. Proto is currently the Chairman and Chief Executive Officer of electronic billing company, Transactis Inc. He founded REMITCO, a remittance processing company where he also served as President for 11 years, which was acquired in 2000 by First Data Corporation. Mr. Proto also founded Financial Telesis (CashFlex), a payment processor to 65 of the top 100 banks in the U.S., which was acquired by CoreStates (now part of Wells Fargo). In 2004, Mr. Proto co-founded Windham Ventures, an investment company focused on life sciences technology-based companies, where he currently serves as a founding partner. Joe is a member of various financial services associations and is a frequent speaker at conferences in the payments industry.

“SpendSmart is evolving. We are expanding our prepaid debit card focus with broader payment offerings, mobile merchant-centric consumer loyalty and rewards solutions, and Prepaid Program Management services for both government and business. The Company is well positioned to capitalize on these growth opportunities and I look forward to actively working with the executive team to lead the direction of SpendSmart in the extensive payments space,” stated SpendSmart Chairman Joe Proto.

“Joe Proto will serve SpendSmart well as our Chairman. He has vast experience and a track record of leading success at a number of payments industry companies. My fellow board members and I are pleased that he has accepted the position of Chairman,” added Mike McCoy, CEO, The SpendSmart Payments Company.

For more information, please visit: www.spendsmartcard.com

About The SpendSmart Payments Company
The SpendSmart Payments Company, Inc. (OTCQB: SSPC) is making money smarter. The Company is expanding its prepaid debit card services from issuing its own cards to select user demographic segments, to the providing SpendSmart Program Manager services to third-party card issuers. The Company’s primary product, the SpendSmart Prepaid MasterCard for teens, offers resources to families with teens who want to learn responsible spending habits. The SpendSmart card provides its users with modern methods of developing financial literacy, centered around a card solution for parents who aim to guide their teens in making sensible, economic choices. The card helps open the lines of communication between parent and teen by tracking spending in real time and, ultimately, creates teachable moments around smart spending habits. For more information, please explore www.spendsmartcard.com.

FORT WORTH, TX–(Marketwired – Nov 21, 2013) – Good Earth Energy Conservation, Inc, a subsidiary of Numbeer, Inc. (OTCQB: NUMB) and provider of electric fleet vehicles for the essential services market, announced today it has shipped four Firefly® Essential Service Vehicles (ESVs) to its customer, Northern Virginia Community College. The college has ordered a total of eight Firefly ESVs from the Company. The remaining four vehicles are scheduled for delivery in the first quarter of 2014.

Northern Virginia Community College (NOVA), the second largest community college in the U.S., is located near Washington D.C. and has six campuses. Good Earth Energy Conservation’s 3-wheeled Firefly® ESVs will be used for parking enforcement and security on the college’s campuses.

“The Firefly® is designed to deliver economic and environmental benefits to our customers. At a cost of less than $.02 per mile to operate, the Firefly® offers a rapid return on investment and is a zero emissions, made-in-the-USA service vehicle,” stated James Emmons the Company’s President and CEO. “Once we get in front of a customer, the value proposition becomes very clear to them. We’re pleased to be receiving more orders from a broad range of customers.”

To learn more about the Firefly® please see the following video: http://fireflyesv.com/work/black-whites/

About Firefly® ESV

The Company’s 3-wheeled Firefly® ESV is engineered and built entirely in the United States. The Firefly uses the longer life cycle lithium iron phosphate battery that has an eight-hour charger compatible with a standard 110v or 220v outlet. The Firefly® is capable of up to 60+ and 90+ miles per charge (extended range model) and performance speeds of up to 45 mph. The basic design of the Firefly® also permits tailoring to the specific requirements of the varying market segments within the essential services market. The vehicle’s modular design will facilitate the export of vehicle kits which can be easily assembled and sold in emerging markets, such as China and other international markets.

For more information about the Company, please visit http://www.FireFlyESV.com

About Numbeer, Inc. and Good Earth Energy Conservation, Inc.

The Company, through its wholly-owned subsidiary, Good Earth Energy Conservation, Inc., founded in 2006 and headquartered in Fort Worth, Texas, is focused on the design, development, assembly and sale of all-electric fleet vehicles for the essential services market, including traffic control/parking enforcement, security, small package delivery, military, maintenance, airport services, warehouses, and other comparable utility applications. The Company’s electric vehicles offer a zero-emission, high performance, low-maintenance and affordable alternative to meeting the specific needs of fleet vehicles in the essential services market.

The Company’s 3-wheeled Firefly® ESV is engineered and built entirely in the United States. The Firefly uses the longer life cycle lithium iron phosphate battery that has an eight-hour charger compatible with a standard 110v or 220v outlet. The Firefly® is capable of up to 60+ and 90+ miles per charge (extended range model) and performance speeds of up to 45 mph. The basic design of the Firefly® also permits tailoring to the specific requirements of the varying market segments within the essential services market. The vehicle’s modular design will facilitate the export of vehicle kits which can be easily assembled and sold in emerging markets, such as China and other international markets.

VIENNA, Va.–(BUSINESS WIRE)–

CEL-SCI Corporation (NYSE MKT: CVM) announced today that it has held the Investigator Meeting for the North American clinical investigators participating in the ongoing international Phase III clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Inj.). Investigators from 14 clinical centers in Canada and the U.S. who are participating in the Phase III clinical trial for head and neck cancer were in attendance. The Investigator Meeting for the 56 clinical centers in Europe that are participating in the study was held in October 2013. A total of approximately 880 patients are expected to be enrolled in the Phase III study. Patients are also being enrolled in the Phase III study in Israel and Taiwan where CEL-SCI’s partners Teva Pharmaceuticals and Orient Europharma are based.

“The number of investigators involved in CEL-SCI’s Phase III trial has increased substantially since we started working with our new clinical research organizations, Ergomed and Aptiv Solutions. At both recent Investigator Meetings critical discussions surrounding the protocol, regulatory issues, enrollment criteria, study procedures and safety issues, among other topics, were discussed,” stated CEL-SCI CEO Geert Kersten. “These meetings are very important to the successful completion of our trial.”

The Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. About 6% of all cancers are head and neck cancer with an estimated 650,000 new cases globally and about 150,000 in the U.S. and Europe. The objective of the study is to demonstrate a statistically significant 10% improvement in overall survival of enrolled patients who are treated with the investigational therapy Multikine plus Standard of Care (SOC) vs. subjects who are treated with SOC only. Multikine is intended to create an anti-tumor immune response to reduce local / regional tumor recurrence and thereby increase the survival of these patients.

Should Multikine treatment plus the current SOC prove successful in demonstrating a statistically significant overall survival advantage in the Phase III study, CEL-SCI will apply to the FDA for a marketing permit to allow the use of Multikine plus the current SOC to treat treatment of naïve patients with advanced primary head and neck cancer. Should this permit be granted by FDA following their review of the totality of the data from the Multikine development program, Multikine would become part of a new standard of care treatment for this indication. The use of Multikine as a part of SOC would represent a multi-billion dollar market. The U.S. Food and Drug Administration (FDA) has already granted orphan drug designation to Multikine in the treatment of advanced primary head and neck cancer.

CEL-SCI, through the newly hired Clinical Research Organization (CROs) Aptiv Solutions and its co-development partner Ergomed, is currently in the process of adding a large number of clinical centers in countries where regulatory approval has already been received to start the Multikine Phase III clinical trial as well as in new countries around the world, with an emphasis on the United States and Europe. The centers are being added to accelerate the enrollment in the clinical trial. These new centers are in addition to the existing study centers and the clinical centers being run in Israel and Taiwan where Teva Pharmaceuticals and Orient Europharma are partners in the Phase III clinical trial.

CEL-SCI recently announced that it had signed a CRADA (Cooperative Research and Development Agreement) with the US Naval Medical Center, San Diego, to develop Multikine as a potential treatment for HIV/HPV co-infected men and women with peri-anal warts. It has also announced that it entered into two co-development agreements with Ergomed to further develop Multikine for cervical dysplasia/neoplasia in women who are co-infected with HIV and HPV and for peri-anal warts in men and women who are co-infected with HIV and HPV.

About Multikine

CEL-SCI’s lead investigational therapy Multikine, is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved by regulatory agencies (e.g., FDA) for use following completion of our clinical development program, Multikine would become an additional and different kind of therapy in the fight against cancer: one that aims to employ our body’s immune system to fight tumors.

About CEL-SCI Corporation

CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body’s natural defense system. The lead investigational therapy is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial. CEL-SCI is also investigating a different peptide-based immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS technology platform. The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu (See Journal of Clinical Investigation – J Clin Invest. 2013; 123(7):2850-2861. doi: 10.1172/JCI67550), Avian Flu (H5N1), and the Spanish Flu, as CEL-SCI scientists are very concerned about the possible emergence of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

For more information, please visit www.cel-sci.com.

CEL-SCI CEO Geert Kersten talks about the future of the company and it’s lead investigational therapy Mutikine.

CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body’s natural defense system. The lead investigational therapy is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial.

BOTHELL, WA–(Marketwired – Nov 18, 2013) – Borneo Resource Investments Ltd. (OTCQB: BRNE), (the “Company” or “Borneo”) a developer of thermal coal concessions and producing gold properties in Indonesia, today announced financial results for the three and nine months ended September 30, 2013.

Highlights include:

$507,771 in revenues in Q3 2013, compared to zero revenues in the same period of 2012 and $212,639 in Q2 2013
$41,201 in net income attributable to Borneo shareholders in Q3 2013, compared to no net income in the same period of 2012 and a net loss in Q2 2013
Q3 2013 marks first full quarter of gold mining at Talawaan Property
Conducted research and feasibility on gold mining at Ratatotok Property
Actively pursued coal concessions as part of Company’s long term strategy
“Producing revenues and profits, Borneo reached an important milestone this quarter. Our financial results provide early validation of our strategy. The value matrix for Borneo is clear. Cash flow producing investments in gold properties will help fund our operations, and build and preserve shareholder value for Borneo, while we pursue longer term, high value investments in high quality thermal coal concessions,” commented Borneo CEO Nils Ollquist.

“Having just completed the acquisition of PT Puncak Kalabat in June of 2013, we swiftly started gold production at the Talawaan Property. We believe we can significantly increase production at Talawaan, as well as begin production at Ratatotok in the coming quarters. Further, the acquisition of Kalabat is proving to be a platform through which we are exploring additional opportunities to expand our precious metals project portfolio, as well as coal concessions,” Ollquist added.

In the three months ended September 30, 2013, Borneo reported revenues of $507,771 from gold production at its Talawaan Property, a 50 hectare property located in the Manado region of Indonesia. Costs applicable to sales were $215,592 for labor and other costs incurred in mining and processing gold. The Company reported zero revenues and zero costs applicable to sales in the third quarter of 2012. Net income attributable to Borneo shareholders was $41,201 or $0.00 per basic and diluted common share for the third quarter of 2013, compared to a net loss attributable to Borneo shareholders of $(265,625) or $(0.00) per basic and diluted common share in the same period of the prior year.

For the nine month period ended September 30, 2013, Borneo reported revenues of $720,410 from gold production at its Talawaan Property. Costs applicable to sales were $310,263 for labor and other costs incurred in mining and processing gold. The Company reported zero revenues and zero costs applicable to sales in the first three quarters of 2012. Net loss attributable to Borneo shareholders was $(246,771), or $(0.00) per basic and diluted common share in the first nine months of 2013 as compared to $(1,658,510) or $(0.02) per basic and diluted common share in the same period of the prior year.

About The Company

Borneo Resource Investments Ltd. is an aggregator of proven precious metal and natural resource concession assets in the Republic of Indonesia. Each concession is a contractual right to explore or develop natural resources in a specific land area. Borneo’s current natural resource portfolio includes two gold projects and a concession for high quality thermal coal. The first gold project is producing while the other is non-producing. Borneo also trades precious metals and thermal coal between Indonesian domestic groups and international buyers. Borneo seeks to opportunistically acquire and market additional natural resource assets.

WILMINGTON, Mass., Nov. 18, 2013 /PRNewswire/ — Implant Sciences Corporation (IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that it has sold its QS-B220 desktop explosives trace detector to a leading regional US airline with growing air cargo revenues. The seven units will be deployed across five locations in the airline’s network.

“The customer was impressed with the QS-B220’s ease of use, non-radioactive source, push-button maintenance, and its low cost of ownership,” stated Implant Sciences’ Vice President of Sales and Marketing, Dr. Darryl Jones. “Buyer after buyer is telling us that the value proposition offered by Implant Sciences is far superior to anything else they’ve seen.”

“As a leading airline that also conducts its own baggage screening, the purchase decision makers at this airline are extremely experienced and knowledgeable about air cargo screening. It was a pleasure working with them, and we look forward to a long-term customer relationship with them,” stated Glenn D. Bolduc, President and CEO of Implant Sciences.

About the QS-B220 Desktop Explosives Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives as well as drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than competing products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. The Company is the third ETD manufacturer, and the sole American-owned company, to currently have product qualification from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. In addition to being named a Qualified Product by TSA on the Air Cargo Screening Technology List, the QS-B220 has received certification from STAC in France, and Designation as a Qualified Anti-Terrorism Technology by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). Implant Sciences’ QS-H150 handheld explosives trace detector is also a Designated Qualified Anti-Terrorism Technology under the SAFETY Act. For further details on the Company and its products, please visit the Company’s website at www.implantsciences.com.

JERUSALEM, Nov. 19, 2013 /PRNewswire/ — Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today that the European Patent Office has allowed the Company’s patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins.”

Europe is one of the world’s largest healthcare markets with an estimated $322 billion market value in 2012, accounting for over one quarter of the world pharmaceutical market, according to a report by the European Federation of Pharmaceutical Industries and Associations. According to Frost & Sullivan the European diabetes market accounted for $8.6 billion in revenues in 2010 and is estimated to grow to $14 billion by 2017, driven by new classes of drugs to treat the disease.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD™) technology is based on over 30 years of research by top research scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently in Phase 2 clinical trials on patients with type 2 diabetes (T2DM) under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), with trials on healthy volunteers (Phase 1b) and T2DM patients (Phase 2a) underway. Oramed is also moving forward with clinical trials of ORMD-0801 for the treatment of type 1 diabetes. The company’s corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please visit http://www.oramed.com

HAIFA, Israel, Nov. 13, 2013 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the South Korean Ministry of Food and Drug Safety (MFDS), formerly the Korea Food & Drug Administration (KFDA), has approved Pluristem’s Investigational New Drug (IND) Application to conduct a Phase II study using PLX-PAD cells for the treatment of Intermittent Claudication (IC), a subset of peripheral artery disease (PAD).

The IND approved by the MFDS mirrors INDs already approved by regulators in the USA, Germany and Israel. South Korea will be the fourth country participating in this multi-national trial involving the use of PLX-PAD in IC. CHA Bio&Diostech Co., Ltd. (KOSDAQ:KS), Pluristem’s South Korean partner, will fund the trial and conduct it in its healthcare facilities.

“Pluristem’s ability to extend our Phase II study of IC into South Korea is important for several reasons,” commented Zami Aberman, Pluristem’s Chairman and CEO. “Partnering with CHA Bio to conduct the clinical trial in their hospitals will accelerate the enrollment and strengthen our relationship with our South Korean partner. Additionally, Pluristem is proud of the fact that our PLX-PAD cells are the first placental-derived allogeneic cells allowed to be imported into South Korea. We at Pluristem believe this is a validation of Pluristem’s expertise in cell therapy in general and PLX potential cell therapy in particular.”

About the Study

Pluristem’s Phase II study of IC is a randomized, placebo-controlled trial that will evaluate the safety and efficacy of two courses of PLX-PAD cells versus placebo, administered via intramuscular injections. The study protocol targets enrollment of 150 patients with IC: Fontaine class IIb, Rutherford category 2-3.

The primary efficacy end point of the trial is the change in the maximal walking distance from baseline during an exercise treadmill test. Secondary endpoints are hemodynamic and quality of life measurements. Safety parameters are also being assessed.

About Intermittent Claudication

IC is a subset of PAD caused by atherosclerosis of the lower extremity arteries. IC is characterized by muscle pain, such as aching, cramping, numbness or a sense of fatigue classically in the calf muscle, which occurs during exercise, such as walking, and is relieved by a period of rest. The prevalence of IC in the United States alone is approximately 14 million patients and representing a cost of approximately $2.5 billion annually to the National Healthcare Bill (References:The SAGE Group and HCUP 2007 Inpatient Data).

About CHA Bio&Diostech

CHA Bio&Diostech Co., Ltd. is a leading biopharmaceutical company headquartered in South Korea; its R&D focuses on stem cells, cell therapeutics, medical device, and new drug development. The company is a member of CHA Health Systems Group, which is comprised of a medical university, medical centers and hospitals located in the US and Korea with in excess of two thousand beds under care, stem cell research centers, personal & preventive medicine, and bio venture divisions. CHA Bio&Diostech has multiple stem cell R&D pipelines in therapeutic areas including Stargardt’s disease, age-related macular disease, Parkinson’s disease, Alzheimer disease, Cerebral Palsy and glioblastoma in mid- to late-stages of development. With its extensive experience and research infra structure, CHA Bio&Diostech has built up multiple strategic relations with major research institutions in the fields of stem cell research and infertility. For more information visit www.chabio.com, the content of which is not part of this press release.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company’s patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company’s proprietary 3D micro-environmental technology and are an “off-the-shelf” product that requires no tissue matching prior to administration.

Pluristem has a strong intellectual property position, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions, and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.

BALTIMORE, MD–(Marketwired – Oct 28, 2013) – Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, announced today that it has initiated research coverage of WhereverTV Broadcasting Corp. (OTC Pink: TVTV), a low-cost net generation subscription television provider offering customers a portable television platform that enables subscribers to view live channels anywhere in the world.

WhereverTV is poised to change the way consumers across the globe access and watch live television and video programming. The Company is leveraging the fast-growing OTT (over the top) platform approach and a unique, proprietary Global Interactive Program Guide to emerge as a leader in the global online television and video market. Industry estimates suggest that this market will grow from $3.8 billion in 2010 to $28.9 billion in 2017.

In the Goldman Opportunity Research report on the Company, analyst Rob Goldman outlines his investment thesis.

“The OTT market is enjoying such unprecedented growth that some industry experts predict that Internet TV will be larger than Facebook and Twitter combined by 2017. With 150,000 free subscribers in 189 countries and more than 1,000 channels, WhereverTV has an enviable head start on potential Internet TV competitors. Given its positioning and unique programming approach, along with the growth of the OTT market, we believe the stock will enjoy a huge rise in conjunction with the execution of subscriber and programming milestones next year.”

This press release contains excerpts of our most recently published research report on WhereverTV. To view the sponsored research report, disclosures and disclaimers, or to download the report in its entirety, please visit www.goldmanresearch.com.

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.

About WhereverTV Broadcasting Corp. (OTC Pink: TVTV): WhereverTV Broadcasting Corp. is the next generation subscription television service, providing consumers with licensed, live-streaming programming identical to existing cable & satellite providers through the Internet via an over the top (OTT) platform. WhereverTV provides a subscription TV over internet service that is an alternative to traditional cable and satellite services, with the added benefits of personalization and portability across many of the most popular mobile and fixed web connected devices. The WhereverTV platform manages licensed and free to air content across these devices and unlimited geographies wherever there is internet connectivity.

For more information, visit the Company’s website: www.wherever.tv.

VIENNA, Va.–(BUSINESS WIRE)–

CEL-SCI Corporation (NYSE MKT: CVM) announced today that it has received approval from the Health Protection Administration, Ministry of Health, of the Croatian Republic to begin enrollment of subjects into the Phase III clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). Croatia is the ninth country into which CEL-SCI has expanded its global Phase III trial. The trial is expected to be conducted in about 100 clinical centers worldwide. CEL-SCI expects to enroll approximately 40 patients in Croatia through four clinical centers.

CEL-SCI plans to accelerate enrollment in its Phase III clinical trial for Multikine by adding a large number of clinical centers in the eight countries where approval to start the trial was previously received and by adding new countries and centers around the world. These new centers are in addition to the Phase III clinical centers run by CEL-SCI’s partners (Teva, Israel and Orient Europharma, Taiwan).

“We are truly seeing major progress in advancing our study since engaging the two new CROs Ergomed and Aptiv Solutions, following our dismissal of the prior CRO that was managing the study, inVentiv, for lack of performance. Ergomed, which is responsible for about 95% of the patient enrollment in the trial, has invested $10 million of its own funds in the Phase III trial and, since then, has invested another $6 million in two other Multikine collaborations with CEL-SCI. Both CROs understand the potential of our science and share our vision, commitment, and diligence to bring this groundbreaking immunotherapy to market,” stated CEL-SCI CEO Geert Kersten.

On November 5, 2013 CEL-SCI announced that a second interim review of the safety data from its open label, randomized, controlled, pivotal Phase III study of Multikine investigational new drug immunotherapy was completed by the Independent Data Monitoring Committee (IDMC). The Committee, which is comprised of world class leaders in head and neck cancer, concluded that the data raised no safety concerns, and recommended that the Phase III study continue unmodified.

The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant, 10% improvement in overall survival of enrolled patients who are treated with Multikine plus Standard of Care (SOC) vs. subjects who are treated with SOC only. Multikine is intended to create an anti-tumor immune response to reduce local / regional tumor recurrence and thereby increase the survival of these patients.

CEL-SCI’s lead investigational therapy, Multikine, is the first immunotherapeutic agent being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved by regulatory agencies (e.g. FDA) for use following completion of our clinical development program, Multikine would become an additional and different kind of therapy in the fight against cancer: one that aims to employ our body’s natural ability to fight tumors.

On October 31, 2013 CEL-SCI announced that it had initiated an arbitration claim against inVentiv Clinical, LLC (f/k/a PharmaNet, LLC and PharmaNet GmbH (f/k/a PharmaNet AG)). CEL-SCI initially retained inVentiv Clinical to conduct the Phase III clinical trial of Multikine. CEL-SCI terminated inVentiv in or about April 2013 and replaced it with two clinical research organizations, Aptiv Solutions, Inc. and Ergomed Clinical Research Ltd. CEL-SCI’s arbitration claim is initiated under the Commercial Rules of the American Arbitration Association alleging (i) breach of contract, (ii) fraud in the inducement, and (iii) common law fraud, and seeks at least $50 million in damages.

About CEL-SCI Corporation

CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body’s natural defense system. Its lead investigational therapy is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial. CEL-SCI is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS technology platform. The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu, as CEL-SCI scientists are very concerned about the possible emergence of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

For more information, please visit www.cel-sci.com.